These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38295963)

  • 1. Evaluation of omadacycline dosing regimens in Chinese using population pharmacokinetic-pharmacodynamic analysis.
    Wang K; Zhu Y; Xu F; Liu L; Liu L; Shi M; Nie J; Reinhart H; Liu J; Gao Y; Pu X
    Eur J Pharm Sci; 2024 Apr; 195():106713. PubMed ID: 38295963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, Safety and Pharmacokinetics/Pharmacodynamics Analysis of Omadacycline in Chinese Healthy Subjects.
    Yang H; Huang Z; Chen Y; Zhu Y; Cao G; Wang J; Guo Y; Yu J; Wu J; Liu L; Deng J; Liu J; Reinhart H; Zhang J; Wu X
    Front Pharmacol; 2022; 13():869237. PubMed ID: 35529438
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae.
    Bhavnani SM; Hammel JP; Lakota EA; Trang M; Bader JC; Bulik CC; VanScoy BD; Rubino CM; Huband MD; Friedrich L; Steenbergen JN; Ambrose PG
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0221321. PubMed ID: 36946741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of omadacycline regimens for community-acquired bacterial pneumonia patients infected with
    Xu G; Liu X; Wang J; Mei Y; Yang D; He C; Zhong L; Zhu J; Ding H; Fang L
    J Chemother; 2024 Apr; ():1-8. PubMed ID: 38650393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent.
    Zhanel GG; Esquivel J; Zelenitsky S; Lawrence CK; Adam HJ; Golden A; Hink R; Berry L; Schweizer F; Zhanel MA; Bay D; Lagacé-Wiens PRS; Walkty AJ; Lynch JP; Karlowsky JA
    Drugs; 2020 Feb; 80(3):285-313. PubMed ID: 31970713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data.
    Lakota EA; Van Wart SA; Trang M; Tzanis E; Bhavnani SM; Safir MC; Friedrich L; Steenbergen JN; Ambrose PG; Rubino CM
    Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32340986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetics Study of Contezolid (MRX-I), a Novel Oxazolidinone Antibacterial Agent, in Chinese Patients.
    Li L; Wu H; Chen Y; Yuan H; Wu J; Wu X; Zhang Y; Cao G; Guo B; Wu J; Zhao M; Zhang J
    Clin Ther; 2020 May; 42(5):818-829. PubMed ID: 32389326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating omadacycline dosing regimens against drug-resistant pathogens including
    Wei XC; Zhao MF; Xiao X
    J Chemother; 2024 Apr; ():1-8. PubMed ID: 38591989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerability and Pharmacokinetics of Contezolid at Therapeutic and Supratherapeutic Doses in Healthy Chinese Subjects, and Assessment of Contezolid Dosing Regimens Based on Pharmacokinetic/Pharmacodynamic Analysis.
    Wu J; Wu H; Wang Y; Chen Y; Guo B; Cao G; Wu X; Yu J; Wu J; Zhu D; Guo Y; Yuan H; Hu F; Zhang J
    Clin Ther; 2019 Jun; 41(6):1164-1174.e4. PubMed ID: 31126694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of levornidazole in healthy subjects and patients, and sequential dosing regimen proposal using pharmacokinetic/pharmacodynamic analysis.
    Cao Y; Li Y; Guo B; Zhang J; Wu X; Yu J; Cao G; Fan Y; Wu H
    Int J Antimicrob Agents; 2023 Apr; 61(4):106754. PubMed ID: 36773938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia.
    Bhavnani SM; Zhang L; Hammel JP; Rubino CM; Bader JC; Sader HS; Gelone SP; Wicha WW; Ambrose PG
    J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii35-iii41. PubMed ID: 30949705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omadacycline Oral Dosing and Pharmacokinetics in Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infection.
    Leviton IM; Amodio-Groton M
    Clin Drug Investig; 2022 Mar; 42(3):193-197. PubMed ID: 35192150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determining optimal dosing regimen of oral administration of dicloxacillin using Monte Carlo simulation.
    Yu W; Ji J; Xiao T; Ying C; Fang J; Shen P; Xiao Y
    Drug Des Devel Ther; 2017; 11():1951-1956. PubMed ID: 28721014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetic Modeling Using Polymyxin B Free Plasma Concentrations From Published Reports and Evaluation of Dosage Regimens Based on Monte Carlo Simulation in Critically Ill Patients.
    Zheng Y; Xu B; Chen S; Liu M; Huang H; Wang J; Wu X
    J Clin Pharmacol; 2023 Sep; 63(9):1036-1044. PubMed ID: 37125471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017.
    Huband MD; Pfaller MA; Shortridge D; Flamm RK
    J Glob Antimicrob Resist; 2019 Dec; 19():56-63. PubMed ID: 30825698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Model-Informed Drug Development, Pharmacokinetic/Pharmacodynamic Cutoff Value Determination, and Antibacterial Efficacy of Benapenem against
    Ji XW; Xue F; Kang ZS; Zhong W; Kuan IH; Yang XP; Zhu X; Li Y; Lv Y
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
    Tanaka SK; Steenbergen J; Villano S
    Bioorg Med Chem; 2016 Dec; 24(24):6409-6419. PubMed ID: 27469981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
    Stass H; Dalhoff A
    Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and Safety of Single-Dose Amphotericin B Colloidal Dispersion in Healthy Chinese Subjects and Population Pharmacokinetic/Pharmacodynamic Analysis to Inform Clinical Efficacy in Invasive Infections Caused by Candida albicans.
    Huang ZW; Yu JC; Wang JJ; Chen YC; Wu JF; Chen YJ; Cao GY; Yang HJ; He JJ; Dai JY; Zhang JY; Zhang W; Yuan J; Li CL; Xu FY; Wang K; Wu XJ; Zhang J
    Clin Ther; 2021 Nov; 43(11):1921-1933.e7. PubMed ID: 34686365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function.
    Canut A; Isla A; Rodríguez-Gascón A
    Int J Antimicrob Agents; 2015 Apr; 45(4):399-405. PubMed ID: 25700566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.